FibroGen Inc

Most Recent

  • uploads///AdobeStock_
    Earnings Report

    Amarin’s Q2 Earnings and Robust 2019 Outlook

    Amarin Corporation (AMRN) reported its Q2 2019 earnings yesterday. Here’s how the stock, investors, and peer pharma stocks reacted.

    By Sushree Mohanty
  • uploads///pills _
    Earnings Report

    What Wall Street Recommends for Amarin after Q4 2018 Results

    On February 27, Amarin (AMRN) closed at $21.18, 5.85% higher than its previous closing price, 801.28% higher than its 52-week low of $2.35, and 9.24% below its 52-week high of $23.33.

    By Margaret Patrick
  • uploads///FGEN
    Company & Industry Overviews

    Understanding FibroGen’s Research Pipeline

    Apart from Roxadustat, other products in FibroGen’s pipeline include Pamrevlumab (or FG-3019) and FG-5200.

    By Kenneth Smith
  • uploads///thermometer _
    Company & Industry Overviews

    Analysts’ Ratings for FibroGen and Its Peers in April 2018

    Of the seven analysts covering FibroGen in April, five have given the stock “strong buy” ratings, while two have given it “hold” ratings.

    By Kenneth Smith
  • uploads///Esbriet revenues
    Company & Industry Overviews

    Esbriet Could Boost Roche’s Revenue Growth in 2H17

    In the first half of 2017, Roche’s (RHHBY) Esbriet reported revenues of CHF 418.0 million, which reflected a ~16.0% growth on a YoY basis.

    By Daniel Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.